Peptide Profiles

PT-141 (bremelanotide / Vyleesi) is the only FDA-approved injectable treatment for hypoactive sexual desire disorder in premenopausal women, a MC4R-biased α-MSH analog with small-to-moderate effect sizes in its approving trials.

An FDA-approved once-daily injectable GHRH(1-44) analog (Egrifta / Egrifta SV / Egrifta WR) approved only for reduction of excess abdominal fat in HIV-associated lipodystrophy, with extensive off-label use that is largely unsupported by independent human evidence.

A synthetic 15-amino-acid peptide studied primarily in animal models for tissue healing, gut repair, and anti-inflammatory effects. Human data is very limited.

A synthetic 29-amino-acid GHRH receptor agonist with four stability substitutions and a ~30-minute half-life, structurally identical to the core of CJC-1295 WITH-DAC but without albumin binding. No published human efficacy trial tests this compound alone.

CJC-1295 DAC is a 30-amino-acid synthetic GHRH analog engineered to covalently bind serum albumin, extending its half-life from minutes to roughly one week and sustaining a single injection's GH / IGF-1 elevation for 6–11 days.

Epitalon is a synthetic four-amino-acid peptide (AEDG), developed by a single research group in St. Petersburg as the putative active fraction of a bovine pineal extract, with in vitro telomerase-upregulation data and preliminary uncontrolled human studies, but no independent in vivo human trial.

A synthetic five-amino-acid pentapeptide that selectively agonizes the ghrelin receptor (GHS-R1a) to trigger pulsatile growth hormone release, studied in one failed human efficacy RCT and not approved anywhere.

Melanotan II is a synthetic, non-selective melanocortin agonist sold online as a "tanning injection." It has never been approved by any drug regulator anywhere, and its harm record is far better documented than its benefits.

MOTS-c is a 16-amino-acid mitochondrially-encoded peptide with observational human evidence tying low circulating levels to metabolic disease, but zero interventional trials of the native peptide in humans.

A synthetic three-amino-acid peptide (Glu-Asp-Arg) developed by the Khavinson group in St. Petersburg and studied almost entirely in cell and animal models as a possible brain-protecting molecule, with very limited independent human data.

A name that refers to either a synthetic 7-amino-acid peptide (Ac-LKKTETQ, the original veterinary product) or the full-length 43-residue thymosin beta-4; research peptide vendors typically sell the latter under the "TB-500" label despite the two being structurally distinct.

KPV is a three-amino-acid C-terminal fragment of α-MSH with documented anti-inflammatory activity in mouse colitis and rabbit corneal-wound models but zero published human clinical trials.